Introduction
============

Myopia, or nearsightedness, affects approximately 25% of the adult population in the United States \[[@r1]-[@r5]\], and is increasing in prevalence. High-grade myopia (\<5 diopters) affects 4.5% of the U.S. population 40 years and older \[[@r5]\], and is a major cause of legal blindness in many developed countries \[[@r6]-[@r8]\], as it predisposes individuals to premature cataracts, glaucoma, retinal detachment, and macular degeneration \[[@r9]-[@r14]\]. Though myopia affects a significant proportion of the population in many countries, it is reaching epidemic proportions in some Asian countries. Taiwan, for example, has a myopia prevalence of 84% among 16- to 18-year-old high school students and a high-grade myopia prevalence of 21% among 18-year-old students \[[@r15]\].

Determining the role of genetic factors in the development of non-syndromic myopia has been influenced by the high prevalence, genetic heterogeneity, and clinical spectrum of this condition, as well as possible modulating environmental effects. However, in the past few years, considerable progress has been made. An X-linked recessive form of myopia was designated the first myopia locus (MYP1, OMIM [310460](http://www.molvis.org/molvis/external.cgi?omim=310460)) on chromosome Xq28 \[[@r16]\]. Reanalysis of this Danish pedigree and another X-linked pedigree of Danish descent suggests that this disease locus involves a cone dysfunction and not simple myopia \[[@r17]\]. By studying several medium to large multigenerational families with autosomal dominant (AD) high-grade myopia, we have found significant linkage at chromosome 18p11.31 (MYP2, OMIM [160700](http://www.molvis.org/molvis/external.cgi?omim=160700)) \[[@r18]\], chromosome 12q23.1-24 (MYP3, OMIM [603221](http://www.molvis.org/molvis/external.cgi?omim=603221)) \[[@r19]\], chromosome 17q21-23 (MYP5, OMIM [608474](http://www.molvis.org/molvis/external.cgi?omim=608474)) \[[@r20]\], and most recently at chromosome 2q37.1 (MYP12, OMIM [609994](http://www.molvis.org/molvis/external.cgi?omim=609994)) \[[@r21]\]. In addition, other research groups studying AD high-grade myopia have found suggestive linkage on chromosome 7q36 (MYP4, OMIM [608367](http://www.molvis.org/molvis/external.cgi?omim=608367)) \[[@r22]\] and significant linkage to chromosomes 7p15.3 \[[@r23]\], chromosome 15q12-13 \[[@r24]\], and chromosome 4q22-q27 (MYP11, OMIM [609994](http://www.molvis.org/molvis/external.cgi?omim=609994)) \[[@r25]\]. Two recent studies have determined loci for common myopia: one in an Ashkenazi Jewish cohort with linkage to chromosome 22q12 (MYP6, OMIM [608908](http://www.molvis.org/molvis/external.cgi?omim=608908)) \[[@r26]\], chromosome 1p36 (MYP14, OMIM [610320](http://www.molvis.org/molvis/external.cgi?omim=610320)) \[[@r27]\], and another in English dizygotic twins with linkage to the PAX6 gene region on chromosome 11p13 (MYP7, OMIM [609256](http://www.molvis.org/molvis/external.cgi?omim=609256)), chromosome 3q26 (MYP8, OMIM [609257](http://www.molvis.org/molvis/external.cgi?omim=609257)), 4q12 (MYP9, OMIM[609257](http://www.molvis.org/molvis/external.cgi?omim=609257)), and 8p23 (MYP10, OMIM [609259](http://www.molvis.org/molvis/external.cgi?omim=609259)) \[[@r28]\]. Most recently X-linked recessive myopia was mapped to Xq23-25 (MYP13, OMIM [300613](http://www.molvis.org/molvis/external.cgi?omim=300613)) region of the X-chromosome \[[@r29]\].

Herein, we study high myopia in a group of Hutterites from South Dakota. The Hutterites were originally refugees from the Anabaptists from Switzerland, Germany, and the Tyrol who settled in Moravia and were united under Jacob Hutter\'s leadership in the 1500s. The four most important Hutterian tenets were adult baptism of believers, community of goods, nonresistance, and the separation of church and state. Due to religious persecution, the Hutterites moved frequently through the centuries, and today about 25% of Hutterites live in the United States. The Hutterites have an internal educational system based within their colonies, starting instruction at age 6 years, and ending at 8th grade (age 13 years). In this study, we exclude linkage to known myopia loci, and report significant linkage of AD nonsyndromic high-grade myopia to a presumptive locus on chromosome 10q21.1 for a large, multi-generational Hutterite family. To our knowledge, this is the first time that high myopia has been studied in a genetically isolated group.

Methods
=======

Subject data collection
-----------------------

A large Hutterite family from South Dakota (Pedigree MYO-101) with 29 members (7 affected) consented to participate in the study. This study was approved by the Institutional Review Board of The University of Minnesota and The Children\'s Hospital of Philadelphia, and adhered to the tenets of the Declaration of Helsinki. This family was selected based on the presence of affected individuals in multiple generations. Individuals with high-grade myopia, defined as a spherical refractive error of \<-5.00 diopters (D) in at least one eye, were considered \"affected\" and individuals with a spherical refractive between -2.00 and -5.00 D in at least one eye were considered \"unknown\", as they had an increased likelihood of developing high-grade myopia. All other individuals (spherical refractive errors \>-2.00 D in both eyes) were considered \"not affected\". No participant had known ocular disease or insult that could predispose to myopia or any known genetic syndrome associated with myopia. Glaucoma, keratoconus, corneal thinning, lenticonus, and dislocated lens were absent in study participants. The family did not display any other systemic genetic traits.

A comprehensive ophthalmic examination and blood collection was performed by one of the authors, TLY, as previously described \[[@r18]\]. Details of the ophthalmic examination are summarized in [Table 1](#t1){ref-type="table"}. DNA was isolated from peripheral blood lymphocytes using standard techniques (Gentra Systems, Minneapolis, MN).

###### Clinical characteristics of pedigree MYO-101.

  ------------- ------------ ---------------------- ------------------ ----------------- ------------------------- ------------------------- --------------------
  **Subject**   **Gender**   **Myopia phenotype**   **Age at onset**   **Age at exam**   **Refractive Error OD**   **Refractive Error OS**   **Ocular history**
  7242          F            NA                     40                 56                +0.25 +0.75x79            +0.25 +0.50x77            \-\--
  7243          M            UK                     14                 32                -2.25 +0.25x90            -1.75 sphere              \-\--
  7244          M            NA                     \-\--              19                -0.25 sphere              Plano                     \-\--
  7245          F            A                      15                 22                -3.75 +0.75x90            -5.25 +1.25x90            \-\--
  7246          F            UK                     14                 17                -3.00 sphere              -2.25 +0.25x110           \-\--
  7247          F            UK                     14                 15                -2.00 sphere              -1.50 +1.00x80            \-\--
  7248          M            UK                     10                 21                -2.00 +0.50x176           -2.75 +1.50x165           \-\--
  7249          M            NA                     30                 54                +2.50 sphere              +2.50 sphere              \-\--
  7251          F            A                      6                  9                 -5.50 +0.75x95            -6.00 +1.25x90            \-\--
  7252          F            A                      7                  12                -8.00 +1.25x90            -6.50 +0.25x90            \-\--
  7253          F            A                      14                 60                -11.25 +0.75x105          -12.25 +0.75x45           \-\--
  7254          M            A                      16                 31                -5.50 +0.50x155           -9.00 +3.50x60            \-\--
  7255          M            NA                     45                 48                -0.50 +0.25x61            -0.25 +0.50x90            \-\--
  7256          M            NA                     \-\--              32                -0.50 sphere              +0.25 sphere              \-\--
  7257          M            NA                     \-\--              26                -0.75 +1.00x75            -0.25 +0.25x95            \-\--
  7258          F            UK                     14                 33                -3.00 +1.25x90            -1.25 +0.75x90            \-\--
  7259          M            NA                     17                 33                -1.25 -1.25x125           -1.50 -0.75x50            \-\--
  7260          M            NA                     30                 69                +0.50 +1.00x9             -1.25 +0.50x16            \-\--
  7261          F            NA                     15                 59                +1.25 +0.25x2             +1.00 +0.50x165           \-\--
  7262          M            NA                     15                 59                -0.75 +1.00x8             -0.25 +0.50x174           \-\--
  7263          M            UK                     10                 24                -1.00 +0.50x75            -2.50 +1.25x80            \-\--
  7264          F            UK                     19                 47                -2.75 +1.25x37            -2.00 +0.75x150           \-\--
  7266          F            UK                     15                 55                -3.00 +1.25x30            -2.5 +0.75x145            \-\--
  7268          F            UK                     9                  54                -4.25 +2.5x85             -3.25 +2.75x70            \-\--
  7270          M            NA                     \-\--              9                 Plano                     Plano                     \-\--
  7272          M            A                      13                 31                -4.25 +1.00x180           -4.25 +1.00x164           s/p LASIK
  7274          M            A                      14                 37                -6.75 +3.75x90            -4.75 +1.75x75            \-\--
  7275          M            NA                     50                 61                +0.5 +0.25x140            Plano+0.75x170            \-\--
  7277          M            NA                     \-\--              35                +0.25 +0.50x79            +0.25 +0.25x105           \-\--
  ------------- ------------ ---------------------- ------------------ ----------------- ------------------------- ------------------------- --------------------

Clinical characteristics of pedigree MYO-101. A=Affected, NA= Not Affected, UK= Unknown, M= Male, F=Female, OD= right eye, OS= left eye, Plano=no refractive error.

Candidate loci screening
------------------------

Initially, we screened 15 candidate gene loci using intragenic and flanking microsatellite markers. These loci included all of the known myopia loci mentioned earlier, except for Xq28, as there was no evidence for an X-linked mode of inheritance. The other candidate regions screened were syndromic loci with high-grade myopia as a consistent phenotype, including Stickler syndrome types 1, 2, and 3; Marfan syndrome; juvenile glaucoma; and Knobloch syndrome. Of these syndromes, all are inherited in an autosomal dominant fashion except for Knobloch syndrome, which is autosomal recessive (AR). As there were many unknown refractive errors (family members not examined or genotyped) in the older generations, we were initially uncertain whether the mode of inheritance was AD or AR.

Genotyping
----------

Genome screening was performed on Pedigree MYO-101 using 382 microsatellite markers from a commercial set (ABI Prism Linkage Mapping Set MD-10; Applied Biosystems, Inc., Foster City, CA) with an average inter-marker distance of 10 cM. The PCR reactions were prepared in 10 μl volumes in 96-well plates with 6 μl of True Allele PCR Premix, 1 μl primer, 1 μl sterile H~2~O, and 2 μl of 3 μg/μl DNA. The conditions recommended by Applied Biosystems were optimized for our PCR machines. The fluorescently labeled PCR products were diluted and pooled (3-7 markers/pool) and run on an automated DNA sequencer (ABI Prism 3730 DNA Analyzer; Applied Biosystems). GeneMapper Software Version 3.0 (Applied Biosystems) was used for automated allele calling, visualization of alleles, and manual genotype verification. After the initial genome screen, markers from the ABI Prism Linkage Mapping Set HD-5 (with an average inter-marker distance of 5 cM) and additional custom-made markers selected from publicly available genetic maps \[[@r30],[@r31]\] were added in all regions with positive LOD scores. Inter-marker recombination frequencies and marker order were obtained from the standard marker databases of the [Marshfield Center for Medical Genetics](http://research.marshfieldclinic.org/genetics/), [Gnthon](http://www.genethon.fr/), and the [UCSC](http://genome.ucsc.edu/) (University of California Santa Cruz) database.

Linkage analysis
----------------

Mendelian error checking was performed using [PEDMANAGER](http://www.genome.wi.mit.edu/ftp/distribution/software/pedmanager/) Version 0.9 software. Mega2 Version 3.0 software \[[@r32]\] was used to create the necessary files required for statistical analysis. [SimWalk2](http://watson.hgen.pitt.edu/docs/simwalk2.html) Version 2.89 software \[[@r33]-[@r35]\] was used for multipoint linkage analysis based on both AD and AR models, as the mode of inheritance was uncertain. A 90% penetrance and a myopia allele frequency of 0.001 were used. Marker allele frequencies were estimated by maximum likelihood based on our pedigree data. Two-point linkage analysis could not be performed because the available linkage analysis programs were not capable of handling the large size and complexity (many loops) of this pedigree.

Positional candidate gene mutation screening
--------------------------------------------

Protocadherin 15 (*PCDH15*) contains 33 exons and encodes a protein of 1,955 amino acids with a molecular mass of about 216 kDa \[[@r36]\]. *ZW10* interactor (*ZWINT*) contains 9 exons and encodes a protein of 277 amino acids with a molecular mass of 32 kDa \[[@r37]\]. We designed and optimized 36 sets of forward and reverse primer pairs for *PCDH15* and 8 for *ZWINT*. The primer pairs were constructed to extend 50 to 200 bp beyond each intron-exon boundary ([Table 2](#t2){ref-type="table"}). For each amplimer, PCR was performed on 150 ng of participant genomic DNA using *Taq* polymerase (Ampli*Taq* Gold; Roche Molecular Systems, Inc., Branchburg, NJ) at 55 °C annealing temperature. Amplified products were separated by agarose gel electrophoresis and visualized by staining with ethidium bromide. Two highly myopic family members (7254 and 7272) were screened, along with 2 unaffected (average spherical refractive error=-0.31 D) family members (7256 and 7257) and 1 external control (C009), a United States caucasian male with no refractive error. If a polymorphism appeared to follow affection status, four additional affected individuals (7245, 7251, 7252, and 7274) were screened for that polymorphism in an attempt to confirm or exclude it as a myopia-causative mutation. Amplicons were sequenced using the BigDye® Terminator v3.1 Cycle Sequencing Kit and were run on an ABI 3730 DNA Analyzer (Applied Biosystems, Foster City, CA). Chromatograms were trimmed for quality and aligned with reference gene sequences from NCBI using Sequencher^TM^ (Gene Codes, Ann Arbor, MI).

###### Primers designed for mutation screening.

  ---------- ----------------------------- -----------------------------
  **Exon**   **Forward Primer**            **Reverse Primer**
  PCDH15                                   
  1          TCACTTGCAATCATTACTACTCTAT     GGCTGACGAACACAGTACAATA
  2          AAAAATCCTGGCTCGCTCTA          AATGTGGCACAGGTAATTAACTATG
  3          TTATTCCAAGTAAAGCATGA          TTTTCCTTTTTAAATATTAATATAC
  4          AAATGAGTTAAAGAAACTGTTGT       TATTTTCTGTCTTATGCTAGATATA
  5          GTTTTCTTGATATTTCTAAACAGTT     TGTACTGAATGAACGAGTGCT
  6          AATAATAGTATCATTACTAATCTGG     GAGCTGATTTTTATGCTGTAACA
  7          ATGAAGAAGTGAGTGGCACA          TTCTATTTTCAGATGATAAGCATGT
  8          AAAATAAAATAACCATGTTGGACT      TTTTTGTTGTTGTTTTTTGAGACTG
  9          AAATATTTCCTTGGAATTGA          TGAGTTTACTGTCTCAGACGTTATA
  10         TAACATAAAACTGCCTACAGTAGCG     TTTGTTCCTCAGCTGATGAAGGG
  11         TTAATTCTCTCTTCTCTAGCTTATG     ATTAGTTAAAAAGAGAACCCTATA
  12         CCAGACATCTCTTTCAGTTCCATAC     TCTTAATACTTTCACGTGGAT
  13         TAATTTCTTCATGAGCATATCGTAT     CCTTTCAAATTGTAAGATTACCTG
  14         AAGAATACTTGCCGCGCTTC          TTGTTGGGGGAAAAAACGACATGGT
  15         CAGATGGAATTTTCATTCACTAGAG     AACAACTGAATAAACAATGCAGTC
  16         AGAAAACAGAAAGGGAAGTACAAC      GATACGAAATGTTTGATTTTACACC
  17         TGATTACTGAGAGGGGAAA           TGTCAAGTCAAAGGTTGCAGC
  18         TTCAGATAGACAAATGCCAGAA        AGTCTTGAAGAATATCCAGCACA
  19         ATTGTCATTGTCATTTCCTCCTT       GGCACACAAACCCTAATAGCA
  20         GTCCTCGTTAAATTGATGCTGT        TTGGAAAATCTATGTTATGGGTC
  21         AATTGAGAGGATGGAAGGCT          TTGCTGTCTTGTGATTCGGTC
  22         CCCAAAGCAACCATTAATTTTTC       ATGAGGATAGAGATCAAAACGCA
  23         CACCTGGTAGGCAGTGAGGAAAT       TTGAAACCCCAAAATATAATGT
  24         ATGAATGTGTGAGGGCAGAGGGT       CAAATGAGGAAAAGGGCAAGGT
  25         TTAGCGAAGTATTGATGTTGA         TCCCAAGGTTTATCCAGAG
  26         AAGCATCATTATCAGTGTCCC         CCTACTGGAGGAATACAAACC
  27         CCCCTCCGTCTAGGCTACTGATA       AAACTGAAAACACTGACCTATGGCT
  28         GTAGGGAAGAGGTAATGTGGG         AGACACTGAGGGCTCCAA
  29         GGCTGTCATCATTTTTCATTT         TTCAGTAACTATTTGGTGGGT
  30         GCTTGTGTTTCAATTAGAGAA         CGCAAAGCCATGTTAC
  31         GAATGACTCTAACGGTAACGAT        TGGAAGCTATAGGCAAACTATCT
  32         CCTGTGGGGATGCTTTTGTAA         AATTTCTGGTTTGGTTTTGGC
  33-1       AACTTGTTTCCTTACATTTCA         CCTTGCCTTATTTCCT
  33-2       AAGAGGTAGCAGCAATCCATT         CGGCAGGCATCAAGTT
  33-3       CCCTCCACCTCCTTCAG             TGGTTTAAGTTGGGTATCTAA
  33-4       TTTTAGTGGGAATATGTGGG          AAAAAATTTAAATTAGGGAGATGAT
  ZWINT                                    
  1          GTGGATGTGGGGAGCGGCGAACGG      AAGAACTTCCACAGGCGCGCGGTCGAG
  2 and 3    GTCTTCAGAAGCCAAGGGGTCG        CCCTGCTGATTTTCCTTTTGGCACGTA
  3 and 4    GGCCATTTGTTTCTACAGATAAGCAAG   GTGGTGGTATGTACAAGATGAGAGCGA
  5          TCAAAGGAGGAAGCAAAACGGTTTTC    CCAAGGTACACCCAGGGGTCTTGAGTA
  6 and 7    CAAATTTACATCTCCAGCAGGTTGTAG   GCAAGAATGCCTCACCCTAGAAC
  8          GAGCTCACTGTTATAATTCTGGTTCAC   AGGTAAATGAGAGATGGAACAGG
  9a         CTTTAAATAACTTGAGACATTGCTAAC   TAATAAACTTTGAAATTTGGTGAGT
  9b         AAATGCATTCTTTCCAAACCTATGTGA   GGTTTGAACACAGGGTGTGCAG
  ---------- ----------------------------- -----------------------------

Forward and reverse primers designed for *PCDH15* and *ZWINT* for mutation screening.

Results
=======

A multi-generational Hutterite family from South Dakota (MYO-101) with high-grade myopia was identified and characterized ([Figure 1](#f1){ref-type="fig"}). The average spherical refractive error of affected individuals of Pedigree MYO-101 (excluding 7272, who had only post-LASIK refractive error information available) was -7.04 diopters (range, -3.75 to -12.25). Although we were not able to obtain pre-LASIK refractive error information for individual 7272, we made an assumption that he was an affected individual for purposes of analysis based on his self-report that he had twice the degree of myopia in diopters prior to his surgery. Two patients from family 101 (7245 and 7274) were anisometropic, with one highly myopic and one moderately myopic eye. The average spherical refractive error for \"unknown\" individuals was -2.39 D. All known syndromic and non-syndromic myopia loci were excluded in this family. The LOD scores at q=0.0 were as follows: *D18S63* (MYP2), -5.232; *D12S78* (MYP3), -0.221; *D7S2465* (MYP4), -5.781; *D17S944* (MYP5), -3.418; *D22S280* (MYP6), -0.960; *D11S904* (MYP7), -0.979; *D2S206* (2q37.1), -2.006; *D7S507* (7p15.3), -7.573; *D15S165* (15q12-13), -3.969; *D12S85* (Stickler syndrome type 1), -4.652; *D1S206* (Stickler syndrome type 2), -1.175; *D6S276* (Stickler syndrome type 3), -2.788; *D15S117* (Marfan syndrome), -5.464; *D1S218* (juvenile glaucoma), -3.131; *D21S1897* (Knobloch syndrome), -8.724.

![Pedigree MYO-101 with familial high-grade myopia. Circles and squares indicate females and males, respectively, while solid symbols show affected individuals. The alleles for the most informative polymorphic markers are shown for each studied individual. Haplotypes were constructed based on the minimum number of recombinations between these markers. The solid and crosshatched bars indicate the two affected haplotypes.](mv-v13-229-f1){#f1}

The multipoint analysis for the initial 10 cM genome screen resulted in no LOD scores \>1.00 under an AR model. However, under an AD model, the multipoint linkage analysis resulted in four LOD score peaks above 1.00, occurring on chromosomes 1p36.32-1p36.31 (LOD=1.207), 1p36.11 (1.131), 9p24.1 (1.095), and 10p11.22-10q11.23 (2.108). Additional flanking microsatellite markers were then genotyped in all of these regions. The LOD scores for the chromosomes 1p and 9p regions reduced or increased negligibly. Haplotype analysis of the 1p36.11 and the 9p24.1 region did not reveal a consistent haplotype segregating with affected individuals. Haplotype analysis of the 1p36.32-1p36.31 region (max LOD score with additional markers =1.330) revealed a consistent affected haplotype in one branch of the family, but not in the other branch. However, on chromosome 10, the additional markers downstream of the initial 10p region produced positive LOD scores without an increase in the maximum multipoint LOD score. Additional markers were used in this region, and yielded a multipoint LOD score under an AD model of 3.22 at marker *D10S1643* on chromosome 10q21.1. The one-unit support interval ranged from marker *D10S539* through marker *D10S1767*, a 2.67 cM region ([Figure 2](#f2){ref-type="fig"} and [Figure 3](#f3){ref-type="fig"}). Haplotype analysis correlated well with the multipoint linkage results, as unaffected individual 7257 had a recombination event either between markers *D10S220* and *D10S539* or between markers *D10S539* and *D10S1643* ([Figure 1](#f1){ref-type="fig"}). It is impossible to determine where the recombination event occurs due to an allele that is common to the affected and unaffected haplotypes at marker *D10S539*. Thus, this unaffected individual has the affected haplotype upstream of *D10S539*, excluding this region from containing the disease gene.

![Multipoint LOD score data for pedigree MYO-101 for chromosome 10q21.1 with markers labeled along the X-axis. LOD scores were plotted against marker distance in centiMorgans (cM).](mv-v13-229-f2){#f2}

![Schematic representation of a linkage map of microsatillite markers located at 10q21.1. The mapping order and genetic distances (in centiMorgans \[cM\]) were primarily obtained from the human genetic map of the Marshfield Center for Medical Genetics. The bold segment denotes the linked interval determined by multipoint linkage and haplotype analysis.](mv-v13-229-f3){#f3}

Interestingly, haplotype analysis also revealed two distinct haplotypes segregating with high-grade myopia ([Figure 1](#f1){ref-type="fig"}), designated in solid black and in crosshatching. This implies that either the mutation is old and has recombined into different genetic backgrounds (haplotypes), or two distinct mutations are responsible for the high-grade myopia seen in this family \[[@r38]\]. Upon inspection of the pedigree, it is evident that there are two distinct branches joined by marriage, making the possibility of two distinct mutations likely. In addition to the seven \"affected\" individuals, three \"unknown\" individuals \[7243, 7248, and 7268 (average spherical refractive error of -2.72 D)\], as well as one unaffected individual (7242), carried either one of the affected haplotypes. Thus, the mutation(s) appear to show incomplete penetrance.

Two known genes were identified within the 2.67 cM region: protocadherin 15 (*PCDH15*) and *ZW10* interacter (*ZWINT*). Direct sequencing of these two genes identified a total of 23 polymorphisms, none of which segregated with the affection status ([Table 3](#t3){ref-type="table"}). There were 21 polymorphisms identified in *PCDH15*; 17 intronic, 2 missense, and 2 silent, out of which 13 were novel. There were 2 identified intronic polymorphisms in *ZWINT*, one of which was novel. All 14 novel polymorphisms have been submitted to the National Center for Biotechnology Information ([NCBI](http://www.ncbi.nlm.nih.gov/)) dbSNP database.

###### Observed sequence polymorphisms in the protocadherin 15 (*PCDH15*) and *ZW10* interacter (*ZWINT*) genes.

  ----------- ------------------------ ---------------------------------- ---------------- ------------ ---------------- ------------------------------------
  **Genes**   **Position**             **nt at GenBank (minus strand)**   **nt changes**   **dbSNP**    **AA changes**   **Sample number (red=affected)**
  PCDH15                                                                                                                 
  Exon 2      83 bp in Exon 2          T                                  T/G              rs11004439   Ser-\>Ala        C009, 7256
  Intron 2    50 bp, 5\' of Exon 3     T                                  G                rs10825347   \-               C009, 7252, 7253
              50 bp, 5\' of Exon 3     T                                  G/T              rs10825347   \-               7254, 7245, 7251, 7274, 7256, 7257
  Intron 3    4 bp, 3\'of Exon3        A                                  A/G              Novel        \-               7254, 7251
  Intron 4    31 bp, 5\'of Exon5       T                                  T/C              rs11594958   \-               7256
  Intron 7    9 bp, 5\'of Exon8        C                                  C/T              rs10740579   \-               C009, 7257, 7272
              9 bp, 5\'of Exon8        C                                  T                rs10740579   \-               7254, 7256
  Exon 8      4 bp in Exonic           C                                  C/T              Novel        Ala-\>Thr        C009
  Intron 9    57 bp, 3\'of Exon8       T                                  G                rs10763098   \-               7254
              57 bp, 3\'of Exon8       T                                  G/T              rs10763098   \-               C009, 7256, 7257, 7272
  Intron 9    71 bp, of 5\' Exon 9     G                                  A                Novel        \-               7254, 7245
              71 bp, of 5\' Exon 9     G                                  G/A              Novel        \-               C009, 7256, 7257, 7252, 7251
  Intron 13   23 bp, of3\' Exon13      G                                  G/A              rs7093302    \-               C009, 7256, 7257, 7252, 7274, 7251
  Intron 14   43 bp, of5\' Exon 15     \-                                 Insertion A      Novel        \-               C009, 7254, 7256, 7257, 7272
  Intron 17   141 bp, 3\' of Exon 17   C                                  C/T              Novel        \-               7254, 7257
  Intron 20   37 bp, 3\' of Exon 20    C                                  C/T              Novel        \-               7256, 7272
  Exon 21     35 bp in Exon 21         G                                  G/A              rs2135720    Ile-\>Ile        7256, 7272
  Intron 21   109 bp, 5\' of Exon 22   T                                  T/C              Novel        \-               C009, 7254
  Intron 22   48 bp, 5\' of Exon 23    G                                  G/A              rs2593107    \-               C009, 7254
  Intron 25   72 bp, 5\' of Exon 26    A                                  A/G              Novel        \-               C009, 7254
  Intron 25   68 bp, 5\' of Exon 26    T                                  T/G              Novel        \-               7254, 7257
  Intron 29   20 bp, 5\' of Exon 30    C                                  C/T              Novel        \-               C009, 7254, 7256, 7257, 7272
  Intron 31   188 bp, 3\' Exon 31      C                                  C/T              Novel        \-               C009, 7254, 7256, 7257, 7272
  Intron 32   120 bp, 3\' of Exon 33   T                                  T/C              Novel        \-               C009, 7254, 7256, 7257, 7272
  Exon 33     215 bp, of Exon 33       C                                  C/A              Novel        Leu-\>Leu        7256, 7272
  ZWINT                                                                                                                  
  Intron5     30 bp, 5\' of Exon 4     C                                  C/T              Novel        \-               7254, 7257
  Intron 3    74 bp, 3\' of Exon 3     G                                  A/A              rs3861049    \-               C009, 7254, 7256, 7257, 7272
  ----------- ------------------------ ---------------------------------- ---------------- ------------ ---------------- ------------------------------------

Affected individual sample numbers are in red. C009, external control; rs, public reference single nucleotide polymorphism (SNP) number from the dbSNP database. Note: Samples C009, 7254, 7256, 7257, and 7272 were sequenced for all exons. Additional samples were sequenced for exons with polymorphisms that initially appeared to segregate with high-grade myopia.

Discussion
==========

This study identifies a novel autosomal dominant locus for high-grade myopia and provides additional evidence for the genetic heterogeneity of myopia. Linkage analysis placed a gene for myopia susceptibility on chromosome 10q21.1, within a 2.67 cM interval. Linkage was excluded to the candidate gene regions for the Stickler syndromes, Marfan syndrome, juvenile glaucoma, and Knobloch syndrome, ensuring that this family did not exhibit a mild phenotypic expression of these conditions. Similarly, linkage was excluded to known autosomal myopia loci. Interestingly, two different haplotypes segregate with high-grade myopia in this family, suggesting the possibility that either the mutation is old and has recombined into different genetic backgrounds (haplotypes), or two distinct mutations are responsible for the high-grade myopia seen in this family.

A search for genes physically mapped between markers *D10S539* and *D10S1767* revealed only two known genes: *PCDH15* (protocadherin 15) and *ZWINT* (*ZW10* interactor). *PCDH15* is a member of the cadherin superfamily of calcium dependent cell-cell adhesion molecules. A 15 cM region encompassing the *PCDH15* gene region was initially implicated in autosomal recessive Usher syndrome in a 1997 study of a Hutterite family \[[@r39]\]. This region was further refined in a study of two Pakistani families segregating Usher syndrome type 1F that demonstrated two homozygous mutations (splice site acceptor mutation and nonsense mutation) in the 33 exon *PCDH15* gene \[[@r36]\]. Additional truncating mutations have since been discovered in other individuals with Usher syndrome. Usher syndrome is characterized by progressive pigmentary retinopathy and sensorineural hearing loss, and individuals with Usher syndrome type 1 have congenital severe-to-profound hearing loss and vestibular dysfunction. Interestingly, individuals with non-syndromic recessive hearing loss (*DFNB23*) have been found to have missense mutations in *PCDH15* \[[@r40]\]. Immunohistochemistry has demonstrated that *PCDH15* is expressed in the photoreceptors, especially in the outer photoreceptor segments of human and monkey retinas \[[@r40]\]. Cones demonstrated strong immunoreactivity and rods demonstrated a diffuse positive signal throughout the photoreceptor layer \[[@r40]\].

*ZWINT* directly specifies the localization of *ZW10* (Zeste White 10) to kinetochores and is essential for mitotic checkpoint signaling, as cells lacking *ZWINT* fail to arrest in mitosis when exposed to microtubule inhibitors, yielding interphase cells with multinuclei \[[@r41]\]. Musio et al. \[[@r42]\] found that inhibition of *INCENP*, *ZWINT*, and *ZW10* resulted in mitotic cells characterized by centromere separation, chromosome aneuploidy, and micronuclei formation, with chromosome morphology similar to that found in Roberts syndrome. The profound effects of *ZWINT* disruption made *ZWINT* a less compelling candidate gene and gene expression patterns of *ZWINT* in ocular tissues are unknown.

Direct sequencing of the coding regions of either gene did not reveal myopia-implicated mutations. Novel SNPs observed with both genes were submitted to the [NCBI](http://www.ncbi.nlm.nih.gov/) dbSNP database. Observed frequencies were submitted for known SNPs. Though there are no other known genes in this region, there is one predicted gene, *AL834134*, which encodes for the hypothetical protein DKFZp667A1711 of unknown function.

We also cannot rule out the possibility of genetic heterogeneity within this family. As mentioned earlier, it appears that the family is made of two distinct branches joined by marriage, so it is quite possible that the 1p36.32-1p36.31 locus (LOD=1.330) is involved in the high-grade myopia of the left branch of the family (affected haplotype with crosshatching) and the 10q21.1 locus is involved in the high-grade myopia of the right branch (affected haplotype in solid black). The small number of affected individuals in one branch may explain the lack of a significant LOD score for the 1p36.32-1p36.31 locus.

In summary, we have mapped a presumptive genetic locus for high-grade myopia. Mutational characterization of the remaining predicted gene in this region may provide additional insight into the molecular mechanisms underlying the development of high-grade myopia and into the regulation of eye growth. However, it is important to note that certain assumptions have been made in the determination of this locus, and further evidence of linkage of myopia to the 10q21.1 region should be sought out.
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